Aquestive Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the stock and has a $10.00 price target.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ram Selvaraju has given his Buy rating due to a combination of factors surrounding Aquestive Therapeutics’ Anaphylm product. The FDA’s decision to waive the advisory committee meeting for Anaphylm’s New Drug Application is a significant risk-reducing factor, suggesting a favorable regulatory outcome. Anaphylm, if approved, would be the first FDA-approved non-invasive, orally delivered epinephrine product for severe allergic reactions, offering a needle-free alternative that could appeal to patients hesitant to use injections.
Additionally, the company’s strategic preparations for Anaphylm’s launch, including optimizing market access and raising awareness through medical forums, indicate a strong potential for market penetration. The projected peak sales of over $280 million by 2034 highlight the product’s commercial promise. The ongoing success of a similar product, neffy, further supports the expectation of Anaphylm’s successful market entry, with its greater convenience potentially driving even higher sales. These factors collectively underpin Selvaraju’s confidence in reiterating a Buy rating with a 12-month price target of $10.
Selvaraju covers the Healthcare sector, focusing on stocks such as Bioxcel Therapeutics, Cognition Therapeutics, and Axsome Therapeutics. According to TipRanks, Selvaraju has an average return of 24.9% and a 56.25% success rate on recommended stocks.
In another report released today, Lake Street also maintained a Buy rating on the stock with a $8.00 price target.